Shreehas P Tambe
Chief Executive Officer and Managing Director
A Biocon veteran, Shreehas assumed the role of CEO and Managing Director in December 2022. He has a strong track record of business success, deep technical and operational expertise, and proven leadership capabilities
Prior to becoming the CEO and Managing Director, Shreehas was Deputy CEO from March 2021 and led end-to-end business operations, steered the company towards sustainable, profitable growth and laid a strong foundation for the future. He has also built and led large, global, cross-functional teams.
Shreehas played an integral role in Biocon Biologics’ historic acquisition of Viatris’ global biosimilars business which will transform the organization into a leading global player, drive future growth and create long-term value for all its stakeholders.
He has been with Biocon since 1997 and has held diverse leadership and operational roles across the value chain including stints in R&D and Operations, leading the Group’s Capital Projects and Global Insulins Business Unit and serving as Chief Operating Officer (COO) for Biocon Biologics. Over the past 25 years, he has helped build and shape Biocon’s biosimilars business and spearheaded the Group’s strategic capital investments including its first overseas facility in Malaysia – Asia’s largest integrated Insulins facility.
Shreehas has also been instrumental in securing regulatory approvals and enabling the successful launch of eight biosimilar products in global markets such as the U.S., EU and Japan.
Shreehas holds a Masters’ degree in Bioprocess Technology from ICT (UDCT), University of Mumbai and has also studied Pharmaceutical Sciences & Technology at the University of Pune. He was conferred the coveted Distinguished Alumnus Award (Professional) by his alma mater, the prestigious ICT, Mumbai, in 2020.